Treatment of GERD w/ esophagitis &/or severe symptoms of reflux. Healing of gastric ulcers associated w/ NSAID therapy. Prevention of gastric & duodenal ulcers associated w/ NSAID therapy in patient at risk. Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.
Gastric antisecretory treatment when the oral route is not possible Patient who cannot take oral medication 20-40 mg once daily. Patients w/ reflux esophagitis 40 mg once daily. Patient treated symptomatically for reflux disease 20 mg once daily. Healing of gastric ulcers associated w/ NSAID therapy & prevention of gastric & duodenal ulcer associated w/ NSAID therapy 20 mg once daily. Prevention of rebleeding of gastric & duodenal ulcers 80 mg as bolus infusion over 30 min, followed by 8 mg/hr continuous IV infusion over 3 days (72 hr) followed by oral acid suppression therapy.
Exclude gastric malignancy before treatment. Increased risk of gastrointestinal infections; co-administration w/ atazanavir; concomitant use w/ clopidogrel. Patients w/ reduced body stores or risk factors for reduced vit B12 absorption; patients at risk of osteoporosis. Severe hypomagnesemia, especially for patients expected to be on prolonged treatment or take other medications that may cause hypomagnesemia. Severe renal & hepatic impairment. Pregnancy & lactation.
A02BC05 - esomeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sign Out
